Form 4: Vaxart Director Elaine J. Heron Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Director Elaine J. Heron reports acquisition of 16,000 shares of common stock and 95,400 stock options in Vaxart, Inc.
Summary
- On June 11, 2024, Elaine J. Heron, a director of Vaxart, Inc., reported acquiring 16,000 shares of common stock due to the vesting of restricted stock units.
- Additionally, Heron acquired 95,400 stock options with an exercise price of $0.77, exercisable beginning June 11, 2024, and expiring on June 11, 2034.
- Following these transactions, Heron directly owns 40,566 shares of common stock and 95,400 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but it's also part of standard compensation practices.
Positives
- The acquisition of shares and stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of shares and options by a director may increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 06/11/2025 | Date of vesting of shares and options, or earlier if the 2025 annual meeting of stockholders occurs before this date. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/12/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.